

# Ankur Jindal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11148310/publications.pdf>

Version: 2024-02-01

18  
papers

338  
citations

840776

11  
h-index

839539

18  
g-index

18  
all docs

18  
docs citations

18  
times ranked

490  
citing authors

#	ARTICLE	IF	CITATIONS
1	Etazolate, a phosphodiesterase 4 inhibitor reverses chronic unpredictable mild stress-induced depression-like behavior and brain oxidative damage. <i>Pharmacology Biochemistry and Behavior</i> , 2013, 105, 63-70.	2.9	47
2	Etazolate rescues behavioral deficits in chronic unpredictable mild stress model: Modulation of hypothalamicâ€“pituitaryâ€“adrenal axis activity and brain-derived neurotrophic factor level. <i>Neurochemistry International</i> , 2013, 63, 465-475.	3.8	38
3	Type 4 phosphodiesterase enzyme inhibitor, rolipram rescues behavioral deficits in olfactory bulbectomy models of depression: Involvement of hypothalamicâ€“pituitaryâ€“adrenal axis, cAMP signaling aspects and antioxidant defense system. <i>Pharmacology Biochemistry and Behavior</i> , 2015, 132, 20-32.	2.9	28
4	Antidepressant-like effect of etazolate, a cyclic nucleotide phosphodiesterase 4 inhibitorâ€”an approach using rodent behavioral antidepressant tests battery. <i>European Journal of Pharmacology</i> , 2012, 689, 125-131.	3.5	22
5	Evaluation of anti-depressant-like activity of linezolid, an oxazolidinone class derivative â€” An investigation using behavioral tests battery of depression. <i>Biochemical and Biophysical Research Communications</i> , 2011, 409, 723-726.	2.1	21
6	Etazolate, a phosphodiesterase-4 enzyme inhibitor produces antidepressant-like effects by blocking the behavioral, biochemical, neurobiological deficits and histological abnormalities in hippocampus region caused by olfactory bulbectomy. <i>Psychopharmacology</i> , 2015, 232, 623-637.	3.1	21
7	Hyperhomocysteinemia leads to exacerbation of ischemic brain damage: Role of GluN2A NMDA receptors. <i>Neurobiology of Disease</i> , 2019, 127, 287-302.	4.4	21
8	Neuropharmacological evaluation of a novel 5-HT <sub>3</sub> receptor antagonist (6g) on chronic unpredictable mild stress-induced changes in behavioural and brain oxidative stress parameters in mice. <i>Indian Journal of Pharmacology</i> , 2014, 46, 191.	0.7	20
9	Antidepressant-like activity of 2-(4-phenylpiperazin-1-yl)-1, 8-naphthyridine-3-carboxylic acid (7a), a 5-HT <sub>3</sub> receptor antagonist in behaviour based rodent models: Evidence for the involvement of serotonergic system. <i>Pharmacology Biochemistry and Behavior</i> , 2013, 109, 91-97.	2.9	18
10	Anxiolytic-like effect of linezolid in experimental mouse models of anxiety. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 40, 47-53.	4.8	18
11	Design, Synthesis and Evaluation of Antidepressant Activity of Novel 2â€“Methoxy 1, 8 Naphthyridine 3â€“Carboxamides as 5â€“HT <sub>3</sub> Receptor Antagonists. <i>Chemical Biology and Drug Design</i> , 2014, 83, 583-591.	3.2	13
12	Molecular modifications by regulating cAMP signaling and oxidant-antioxidant defence mechanisms, produce antidepressant-like effect: A possible mechanism of etazolate aftermaths of impact accelerated traumatic brain injury in rat model. <i>Neurochemistry International</i> , 2017, 111, 3-11.	3.8	12
13	Design, Synthesis, and Pharmacological Evaluation of Novel 2â€“(4â€“substituted piperazinâ€“1-yl) 1, 8 Naphthyridine 3â€“Carboxylic Acids as 5â€“HT <sub>3</sub> Receptor Antagonists for the Management of Depression. <i>Chemical Biology and Drug Design</i> , 2014, 84, 721-731.	3.2	11
14	Piperazine Analogs of Naphthyridineâ€“3â€“carboxamides and Indoleâ€“2â€“carboxamides: Novel 5â€“HT <sub>3</sub> Receptor Antagonists with Antidepressantâ€“Like Activity. <i>Archiv Der Pharmazie</i> , 2015, 348, 34-45.	4.1	11
15	Protective effects of a novel 5-HT <sub>3</sub> receptor antagonist, N-n-butyl-3-methoxy quinoxaline-2-carboxamide (6o) against chronic unpredictable mild stress-induced behavioral changes and biochemical alterations. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 122, 234-239.	2.9	10
16	2-(4-substituted piperazin-1-yl)-1,8-naphthyridine-3-carboxylic acids: Novel 5-HT <sub>3</sub> receptor antagonists with anxiolytic-like activity in rodent behavioral models. <i>Canadian Journal of Physiology and Pharmacology</i> , 2013, 91, 848-854.	1.4	9
17	Effect of combination of ketanserin and escitalopram on behavioral anomalies after olfactory bulbectomy: Prediction of quick onset of antidepressant action. <i>Indian Journal of Pharmacology</i> , 2014, 46, 639.	0.7	9
18	Neuropharmacological effect of novel 5-HT <sub>3</sub> receptor antagonist, N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n) on chronic unpredictable mild stress-induced molecular and cellular response: Behavioural and biochemical evidences. <i>Pharmacological Reports</i> , 2014, 66, 804-810.	3.3	9